Contemporary options and future perspectives: three examples highlighting the challenges in testicular cancer imaging

• Published in: World journal of urology 2022-02, Vol.40 (2), p.307-315
• Main Authors: Wakileh, Gamal Anton, Ruf, Christian, Heidenreich, Axel, Dieckmann, Klaus-Peter, Lisson, Catharina, Prasad, Vikas, Bolenz, Christian, Zengerling, Friedemann
• Format: Article
• Language: English
• Subjects: Computed tomography; Humans; Lymph nodes; Magnetic resonance imaging; Male; Medicine; Medicine & Public Health; Nanoparticles; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal - diagnostic imaging; Neoplasms, Germ Cell and Embryonal - pathology; Neoplasms, Germ Cell and Embryonal - therapy; Nephrology; Oncology; Positron Emission Tomography Computed Tomography - methods; Positron-Emission Tomography; Radiomics; Testes; Testicular cancer; Testicular Neoplasms - diagnostic imaging; Testicular Neoplasms - therapy; Topic Paper; Tumor markers; Tumors; Ultrasonography; Urology
• ISSN: 0724-4983; 1433-8726; 1433-8726
• DOI: 10.1007/s00345-021-03856-6

Purpose One of the main issues in testicular germ cell tumors (TGCTs) management is to reduce the necessary amount of treatment to achieve cure. Excess treatment burden may arise from late diagnosis of the primary as well as from false positive or negative staging results. Correct imaging is of paramount importance for successful management of TGCT. The aim of this review is to point out the current state of the art as well as innovative developments in TGCT imaging on the basis of three common challenging clinical situations. Methods A selective literature search was performed in PubMed, Medline as well as in recent conference proceedings. Results Regarding small testicular lesions, recent studies using elastography, contrast-enhanced ultrasound or magnetic resonance imaging (MRI) showed promising data for differentiation between benign and malignant histology. For borderline enlarged lymph nodes FDG-PET-CT performance is unsatisfactory, promising new techniques as lymphotropic nanoparticle-enhanced MRI is the subject of research in this field. Regarding the assessment of postchemotherapeutic residual masses, the use of conventional computerized tomography (CT) together with serum tumor markers is still the standard of care. To avoid overtreatment in this setting, new imaging modalities like diffusion-weighted MRI and radiomics are currently under investigation. For follow-up of clinical stage I TGCTs, the use of MRI is non-inferior to CT while omitting radiation exposure. Conclusion Further efforts should be made to refine imaging for TGCT patients, which is of high relevance for the guidance of treatment decisions as well as the associated treatment burdens and oncological outcomes.